## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	S)															
1. Name and Address of Reporting Person * FRAZIER ALAN D					2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director X 10% Owner				
(Last) (First) (Middle) C/O FRAZIER & COMPANY, 601 UNION STREET, SUITE 3200					3. Date of Earliest Transaction (Month/Day/Year) 02/19/2004						-	Office	r (give title belo	ow)	Other (specify	below)	
(Street) SEATTLE, WA 98101					4. If Amendment, Date Original Filed(Month/Day/Year) 02/23/2004							6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui							quire	ired, Disposed of, or Beneficially Owned				
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	Execu		(Instr. 8)		4. Securities Acquii (A) or Disposed of (Instr. 3, 4 and 5)		of (I	(D) Benefici Reported		ant of Securities ally Owned Following d Transaction(s)		Ownership Form:	Beneficial	
				(Month/Day/Year)			ode	V	Amou	(A) or (D)	Prio		Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock 02/1		02/19/2004			;	S		75,01° (1) (2)	11) 1 1710145		45 (1) (2) (	3)	I	See Footnote (3)			
Reminder:	Report on a s	separate line f	or each class of secu Table II -	Deriva	ntive Securi	ties Ac	equire	Pers cont the f	ons whained if	ho respondin this for splays a	orm a a cur enefic	are n rrent cially	not requ ly valid	ction of inf uired to res OMB conf	spond unle	ess	C 1474 (9-02)
1 7711 6		2 75 .:	124 5 1	· · ·	uts, calls, w		ts, op						,	0 D : C	0.37. 1	6 10	11.37.
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/	Execution D	ate, if	Code	5. Numl of Deriv Secur Acqu (A) o Dispo of (D (Instr 4, and	vative rities ired rosed )	and Expiration Date (Month/Day/Year)  and Expiration Date Unit (Month/Day/Year)		Amou Jnder Securi Instr.	ount of erlying urities r. 3 and Derivative Security (Instr. 5)		9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owner Form of Deriva Securit Direct or Indi	of Benefic Owners y: (Instr. 4		
					Code V	(A)	(D)	Date Exer	cisable	Expirati Date	T T	Γitle	Amount or Number of Shares				

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director 10% Owner		Officer	Other		
FRAZIER ALAN D C/O FRAZIER & COMPANY 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101	X	X				

#### **Signatures**

/s/ Alan D. Frazier	03/23/2004			
**Signature of Reporting Person	Date			

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This amendment is being filed to report the actual number of shares sold by Frazier Healthcare IV, L.P. (6,819 shares) and Frazier Affiliates IV, L.P. (35 shares) upon the exercise by the Underwriters of their option to cover over-allotments, which option was granted pursuant to the Underwriting Agreement dated February 19, 2004, by and between the Issuer, the Selling Shareholders (as defined therein) and the Underwriters (as defined therein), which was previously filed as Exhibit 1.1 to the Form 8-K of the Issuer filed February 20, 2004.
- The Form 4 reports filed by Alan D. Frazier on February 23 and 26, 2004 reported the maximum number of shares that might have been purchased by the Underwriters. On March 19, 2004, the over-allotment option was exercised and the actual number of shares sold became known. Previously, it was assumed that 10,221 shares held by Frazier Healthcare IV, L.P. and 52 shares held by Frazier Affiliates IV, L.P., had been sold to the Underwriters as of February 19, 2004 in connection with the exercise of the over-allotment option.
  - Includes 1,220,869 shares held by Frazier Healthcare IV, L.P., 6,197 shares held by Frazier Affiliates IV, L.P., 481,397 shares held by Frazier Healthcare II, L.P. and 1,682 shares held by Frazier & Company, Inc. Alan D. Frazier, a director of Rigel since October 1997, is one of five managing members of FHM IV, L.L.C., the general partner of FHM IV, L.P., which is the general partner of both Frazier Healthcare IV, L.P. and Frazier Affiliates IV, L.P. Mr. Frazier is the president and controlling shareholder of
- Frazier & Company, Inc. Frazier & Company, Inc. is the managing member of Frazier Management L.L.C., which is the managing member of Frazier Healthcare II, L.P. Mr. Frazier disclaims beneficial ownership of the shares, except to the extent of his proportionate pecuniary interest therein. This filing does not constitute admission that the reporting person is a beneficial owner of the shares for purposes of Section 16 or for any other purposes.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.